Creative Medical Technology Holdings, Inc. (CELZ)
0.623
+0.02
(+2.81%)
USD |
NASDAQ |
Nov 06, 10:31
Creative Medical Technology Holdings Enterprise Value : -4.881M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -4.881M |
| November 04, 2026 | -4.583M |
| November 03, 2026 | -4.443M |
| November 02, 2026 | -4.767M |
| October 30, 2026 | -4.563M |
| October 29, 2026 | -4.411M |
| October 28, 2026 | -4.141M |
| October 27, 2026 | -4.334M |
| October 26, 2026 | -4.193M |
| October 23, 2026 | -4.011M |
| October 22, 2026 | -3.790M |
| October 21, 2026 | -3.995M |
| October 20, 2026 | -3.916M |
| October 19, 2026 | -4.117M |
| October 16, 2026 | -4.004M |
| October 15, 2026 | -3.506M |
| October 14, 2026 | -3.801M |
| October 13, 2026 | -3.492M |
| October 12, 2026 | -3.355M |
| October 09, 2026 | -3.372M |
| October 08, 2026 | -3.229M |
| October 07, 2026 | -3.044M |
| October 06, 2026 | -2.970M |
| October 05, 2026 | -2.842M |
| October 02, 2026 | -2.671M |
| Date | Value |
|---|---|
| October 01, 2026 | -2.702M |
| September 30, 2026 | -2.748M |
| September 29, 2026 | -2.549M |
| September 28, 2026 | -2.258M |
| September 25, 2026 | -2.128M |
| September 24, 2026 | -2.518M |
| September 23, 2026 | -2.493M |
| September 22, 2026 | -2.712M |
| September 21, 2026 | -2.290M |
| September 18, 2026 | -2.544M |
| September 17, 2026 | -3.118M |
| September 16, 2026 | -3.479M |
| September 15, 2026 | -3.070M |
| September 14, 2026 | -3.116M |
| September 11, 2026 | -2.579M |
| September 10, 2026 | -2.646M |
| September 09, 2026 | -2.063M |
| September 08, 2026 | -1.804M |
| September 04, 2026 | -1.609M |
| September 03, 2026 | -1.934M |
| September 02, 2026 | -1.479M |
| September 01, 2026 | -1.674M |
| August 31, 2026 | -1.479M |
| August 28, 2026 | -1.414M |
| August 27, 2026 | -1.414M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
| Vericel Corp. | 2.582B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.511M |
| Total Expenses (Quarterly) | 1.512M |
| EPS Diluted (Quarterly) | -0.4085 |
| Earnings Yield | -285.3% |
| Normalized Earnings Yield | -285.33 |